Reply to: “Incidence of grade 3–4 liver injury under immune checkpoints inhibitors: A retrospective study”
Author(s): ,
Didier Samuel
Affiliations:
AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, Univ Paris-Sud, UMR-S 1193, Université Paris-Saclay Villejuif, DHU Hepatinov, France
Corresponding Author. Address: Centre Hépatobiliaire, Hôpital Paul Brousse, Groupe Hospitalier Paris Sud, DHU Hepatinov, RHU Ilite, 12 Avenue Paul Vaillan Couturier, 94800 Villejuif, France; Tel.: + 33 1 45 59 34 03; fax: + 33 1 45 59 38 57.
,
Catherine Guettier
Affiliations:
AP-HP Hôpital Bicêtre, Department of Pathology, Le Kremlin-Bicêtre, France
,
Aurelien Marabelle
Affiliations:
Département d'innovation thérapeutique et d'Essais Précoces (DITEP), Institut Gustave-Roussy, Université Paris Saclay, Villejuif, France
,
Caroline Robert
Affiliations:
Dermatology Unit, Department of Medical Oncology, Gustave Roussy, Paris Sud University, Villejuif, France
,
Olivier Lambotte
Affiliations:
APHP Hôpital Bicêtre, Service de Médecine Interne et Immunologie Clinique, Université Paris Sud, CEA, DSV/iMETI, Division of Immunovirology, IDMIT, INSERM, U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin Bicêtre, France
,
Stephane Champiat
Affiliations:
Département d'innovation thérapeutique et d'Essais Précoces (DITEP), Institut Gustave-Roussy, Université Paris Saclay, Villejuif, France
,
Barbara Papouin
Affiliations:
Univ Paris-Sud, UMR-S 1193, Université Paris-Saclay, France
,
Jean-Marie Michot
Affiliations:
Département d'innovation thérapeutique et d'Essais Précoces (DITEP), Institut Gustave-Roussy, Université Paris Saclay, Villejuif, France
Eleonora De Martin
Affiliations:
AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, Univ Paris-Sud, UMR-S 1193, Université Paris-Saclay Villejuif, DHU Hepatinov, France
EASL LiverTree™. Samuel D. Dec 1, 2018; 256751
Prof. Didier Samuel
Prof. Didier Samuel

Access to this content is an EASL members and LiverTree™ Privileged Users benefit.

Journal Abstract
References
Discussion Forum (0)
Rate & Comment (0)
This article does not have an abstract to display.
[1]. E. De Martin - Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
[2]. L. Vigano - Reversibility of chemotherapy-related liver injury
[3]. B. Sangro - A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
[4]. A.B. El-Khoueiry - Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
[5]. J. Larkin - Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
[6]. J.D. Wolchok - Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
[7]. M. Johncilla - Ipilimumab-associated Hepatitis: Clinicopathologic Characterization in a Series of 11 Cases
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings